DZ Bank Knock-Out REGN/ DE000DQ28S96 /
| 28/06/2024 21:34:50 | Chg.+0.010 | Bid21:59:41 | Ask21:59:41 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.760EUR | +0.57% | 1.780 Bid Size: 5,000 |
1.790 Ask Size: 5,000 |
Regeneron Pharmaceut... | 862.2857 USD | 31/12/2078 | Call |
GlobeNewswire
28/06
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...
GlobeNewswire
27/06
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...
GlobeNewswire
26/06
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
GlobeNewswire
26/06
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...
GlobeNewswire
22/06
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
18/06
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD ...
GlobeNewswire
16/06
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...
GlobeNewswire
13/06
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
11/06
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire
05/06
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
04/06
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
03/06
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroG...
GlobeNewswire
31/05
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
31/05
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire
31/05
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
31/05
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire
28/05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
23/05
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire
21/05
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
20/05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
